Overview
All current immune biomarkers, individually or combined, are insufficiently accurate or robust to enable treatment decisions. The overarching aim of this project is to test our current working hypothesis that monitoring COX-2-associated protumourigenic inflammation represents an independent immune-relevant biomarker.
This builds on our work demonstrating that gene signatures that integrate pro- and anti-tumourigenic inflammatory factors can have both prognostic and predictive value. We are further testing and refining our gene signatures for their utility to anticipate patient prognosis and response to immunotherapy while simultaneously developing clinically compatible methods to monitor their levels in patient samples.
